Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co EBITDA per Share

The EBITDA per Share of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Oct 19, 2026 is -1.18 CNY. In the previous year, EBITDA per Share was -0.84 CNY — a change of 40.68% (lower).

EBITDA per Share

-1.18CNY

YoY

40.68%

Last updated:

EBITDA per Share of Tibet Duo Rui Pharmaceutical Co is 2025 -1.18 CNY. EBITDA per Share of Tibet Duo Rui Pharmaceutical Co was 2024 -0.84 CNY. It decreases by 40.68% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
0.71 CNY
Jan 1, 2019
1.13 CNY
Jan 1, 2020
1.43 CNY
Jan 1, 2021
1.08 CNY
Jan 1, 2022
0.36 CNY
Jan 1, 2023
0.29 CNY
Jan 1, 2024
-0.84 CNY
Jan 1, 2025
-1.18 CNY
The Tibet Duo Rui Pharmaceutical Co EBITDA per Share history
YEAREBITDA per ShareYoY
-1.18CNY+40.68%
-0.84CNY-391.78%
0.29CNY-19.74%
0.36CNY-66.77%
1.08CNY-24.42%
1.43CNY+26.45%
1.13CNY+60.09%
0.71CNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co Ltd is a pharmaceutical company based in Wuhan, China, operating within the healthcare sector. The company focuses on the research, development, manufacturing, and sale of chemical preparations and their raw materials. It went public on the Shenzhen Stock Exchange on September 29, 2021, with ticker 301075.SZ and ISIN CNE100004RW5. The company employs 318 full-time staff and is headquartered in Wuhan, Hubei. Its core product is sodium acetate ringer injection, used for replenishing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection. The company's website is http://www.duoruiyy.com/. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

EBITDA per Share of Tibet Duo Rui Pharmaceutical Co is -1.18 CNY in 2025.

EBITDA per Share of Tibet Duo Rui Pharmaceutical Co changed from -0.84 CNY to -1.18 CNY, representing a 40.68% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Tibet Duo Rui Pharmaceutical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Tibet Duo Rui Pharmaceutical Co